Mitochondria-enriched Genetically Engineered Cells and Uses Thereof
Summary
The USPTO granted Patent No. US12605410B2 to Minovia Therapeutics Ltd. covering pharmaceutical compositions of mitochondrially-enriched genetically engineered T cells and methods of using such cells to treat diseases and disorders. The patent, with 18 claims, was filed on March 30, 2021. This IP grant gives Minovia enforceable rights to its cell engineering technology through the patent term.
What changed
The USPTO issued Patent No. US12605410B2 to Minovia Therapeutics Ltd., covering pharmaceutical compositions containing mitochondrially-enriched genetically engineered T cells and methods of treatment using such cells. The patent includes 18 claims across multiple CPC classifications spanning immunology, genetic engineering, and oncology applications.
Pharmaceutical and biotechnology companies developing engineered cell therapies should review this patent when designing similar T cell or immunotherapy programs. Freedom-to-operate analyses for cell engineering technologies should account for this granted IP. The patent provides Minovia with enforceable exclusivity for the specified compositions and treatment methods through the patent term.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Mitochondria-enriched genetically engineered cells and uses thereof
Grant US12605410B2 Kind: B2 Apr 21, 2026
Assignee
Minovia Therapeutics Ltd.
Inventors
Natalie Yivgi-Ohana, Noa Sher, Moriya Blumkin, Elad Jacoby
Abstract
The present invention is based on the discovery that cells enriched with mitochondria are useful for treating diseases and disorders. Disclosed are pharmaceutical compositions of mitochondrially-enriched genetically engineered T cells and methods of treatment using mitochondrially-enriched genetically engineered T cells.
CPC Classifications
A61K 35/545 A61K 38/1774 A61K 40/11 A61K 40/31 A61K 40/4211 A61K 35/28 A61K 35/17 A61K 2039/5156 A61K 39/0011 C12N 5/0636 C12N 15/86 C12N 2502/025 C12N 2740/10043 C12N 2510/00 A61P 35/00 C07K 14/7051
Filing Date
2021-03-30
Application No.
17910304
Claims
18
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.